LYNPARZA® (olaparib) Approved in the EU for Use as First-Line Maintenance Therapy in Patients With BRCA-Mutated Advanced Ovarian Cancer
AstraZeneca and Merck’s LYNPARZA Reduced the Risk of Disease Progression or Death by 70% Compared to Placebo Following Response to Platinum-Based Chemotherapy in Phase 3 SOLO-1 Trial
LYNPARZA is the Only PARP Inhibitor Approved in the EU for This Indication
KENILWORTH, N.J.–(BUSINESS WIRE)–AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United
States and Canada, today announced that the European Commission has
approved LYNPARZA as monotherapy for the maintenance treatment of adult
patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (BRCAm)
(germline and/or somatic) high-grade epithelial ovarian, fallopian tube
or primary peritoneal cancer who are in response (complete or partial)
following completion of first-line platinum-based chemotherapy.
Media:
Pamela Eisele
(267) 305-3558
Michael Close
(267) 305-1211
Investors:
Teri Loxam
(908) 740-1986
Michael DeCarbo
(908) 740-1807
